UCB SA (EUR)
UCB
Overview
Key Information
Legal Documents
Financials
Overview
| Sector | Healthcare |
| Industry | Biotechnology |
| Day Range | 66.30 | 67.88 |
| 52-Wk Range | 62.26 | 80.06 |
| Last Close | 66.86 |
| Mkt Cap (m) | 12,594.20 |
| Dividend yield | 1.81% |
| ISIN | BE0003739530 |
| Volume | 310,741 |
| Exchange Venue | BRU |
Company Profile
UCB SA is engaged in the development of novel therapies for the treatment of central nervous system and immunological diseases.
Key Information
| Price/Earning | 19.27 |
| Price/Book | 1.94 |
| Price/Sales | 2.68 |
| P/CF | 13.23 |
| Rev Growth (3 year avg) | 6.12 |
| EPS Growth (3 year avg) | 0.09 |
| Operating Margin % | 23.83 |
| Net Margin % | 17.27 |
| Return on Equity | 13.20 |
| Debt/Equity | 0.24 |
Legal Documents
Annual Report
| en 31/12/2018 |
Financials
Income Statement
| EUR | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 |
| Revenue (m) | 3,411 | 3,344 | 3,876 | 4,178 | 4,530 | 4,632 |
| Operating Income (m) | 465 | 368 | 638 | 921 | 1,115 | 1,104 |
| Net Income (m) | 207 | 209 | 623 | 520 | 753 | 800 |
| Basic EPS | 1.14 | 1.10 | 3.25 | 2.76 | 4.00 | 4.24 |
| Avg. Diluted Shares Outstanding (m) | 182 | 190 | 192 | 188 | 188 | 188 |
Balance Sheet
| EUR | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 |
| Current Assets (m) | 2,421 | 2,501 | 2,838 | 2,331 | 2,677 | 2,950 |
| Non Current Assets (m) | 7,486 | 7,647 | 8,118 | 7,881 | 7,240 | 7,564 |
| Total Assets (m) | 9,907 | 10,148 | 10,956 | 10,212 | 9,917 | 10,514 |
| Current Liabilities (m) | 2,336 | 2,336 | 3,061 | 2,418 | 1,949 | 2,238 |
| Total Liabilities (m) | - | - | - | - | - | - |
| Total Equity (m) | 4,603 | 5,002 | 5,672 | 5,584 | 5,813 | 6,310 |
Cash Flows
| EUR | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 |
| Operating Cash Flows (m) | 298 | 512 | 245 | 427 | 927 | 1,089 |
| Capital Expenditure (m) | -353 | -161 | -146 | -138 | -209 | -341 |
Figures are quoted in EUR unless stated otherwise
-0.30 (-0.45%)
€
66.56
Last Price
© 2019 MeDirect Bank (Malta) plc. All rights reserved.